Full Press Release Details
FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma.
REGN
FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma
Key Takeaway: FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma